Should Minimal Residual Disease Monitoring in Acute Lymphoblastic Leukemia be Standard of Care?
- 29 February 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Hematologic Malignancy Reports
- Vol. 7 (2), 170-177
- https://doi.org/10.1007/s11899-012-0115-4
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemiaBlood, 2011
- Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemiaNature Genetics, 2011
- Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemiaBlood, 2010
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationThe New England Journal of Medicine, 2009
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2009
- Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic LeukemiaJama-Journal Of The American Medical Association, 2009
- Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemiaThe Lancet Oncology, 2009
- Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01Blood, 2007
- A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemiaBlood, 2007
- Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2Blood, 2006